CHPA Continues Pushing for an Appropriate Path Forward for Dietary Supplement Listings

CHPA’s President and CEO Scott Melville released the below statement today following the Senate HELP Committee’s Markup of S.4348, the FDA Safety and Landmark Advancement (FDASLA) Act of 2022:
Share page:

 

“While CHPA remains highly supportive of an appropriate listing system for dietary supplements that will enhance consumer safety, we are strongly concerned that the dietary supplement provisions of this legislation are overly broad and will place unnecessary and costly burdens on the entire industry. Moreover, the legislation falls short of the comprehensive reforms needed to appropriately and effectively modernize the regulatory framework for dietary supplements.

 

“CHPA remains committed to working with congressional leaders in both parties on an appropriate listing system that paves the way for increased visibility into the dietary supplement marketplace, while also providing consumers with the assurances they deserve regarding dietary supplements sold in the United States.”

###